Can-Fite BioPharma Ltd.

TASE:CANF Stock Report

Market Cap: ₪40.9m

Can-Fite BioPharma Management

Management criteria checks 4/4

Can-Fite BioPharma's CEO is Motti Farbstein, appointed in Aug 2003, has a tenure of 21.42 years. total yearly compensation is $467.00K, comprised of 66.4% salary and 33.6% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth ₪24.53. The average tenure of the management team and the board of directors is 21.4 years and 16.4 years respectively.

Key information

Motti Farbstein

Chief executive officer

US$467.0k

Total compensation

CEO salary percentage66.4%
CEO tenure21.4yrs
CEO ownership0.00006%
Management average tenure21.4yrs
Board average tenure16.4yrs

Recent management updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19
It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Recent updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19
It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

Jun 30
Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Mar 08
We're Not Very Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Nov 21
Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Deliver On Growth Plans?

Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely

May 16
Can-Fite BioPharma (TLV:CANF) Will Have To Spend Its Cash Wisely

We're A Little Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

Jan 31
We're A Little Worried About Can-Fite BioPharma's (TLV:CANF) Cash Burn Rate

CEO Compensation Analysis

How has Motti Farbstein's remuneration changed compared to Can-Fite BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$7m

Dec 31 2023US$467kUS$310k

-US$8m

Sep 30 2023n/an/a

-US$9m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$471kUS$298k

-US$10m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$484kUS$291k

-US$15m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$468kUS$313k

-US$15m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$17m

Mar 31 2020n/an/a

-US$13m

Dec 31 2019US$277kUS$195k

-US$13m

Sep 30 2019n/an/a

-US$11m

Jun 30 2019n/an/a

-US$8m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018US$331kUS$186k

-US$7m

Compensation vs Market: Motti's total compensation ($USD467.00K) is about average for companies of similar size in the IL market ($USD425.15K).

Compensation vs Earnings: Motti's compensation has been consistent with company performance over the past year.

CEO

Motti Farbstein (60 yo)

21.4yrs

Tenure

US$467,000

Compensation

Mr. Motti Farbstein serves as a Chief Operating and Financial Officer at Can-Fite BioPharma Ltd. since May 2005 and serves as its Chief Executive Officer since June 30, 2023. Mr. Farbstein served as Chief...

Leadership Team

NamePositionTenureCompensationOwnership
Pnina Fishman
Founder19.3yrsUS$703.00k0.013%
₪ 5.3k
Motti Farbstein
CEO and Chief Financial & Operating Officer21.4yrsUS$467.00k0.000060%
₪ 24.5
Sari Fishman
Vice President of Business Development11yrsUS$373.00kno data
Ilan Cohn
Co-Founder & Director30.3yrsno data0.0065%
₪ 2.7k
Stephen A. Harrison
Member of Clinical Advisory Board & Consulting Chief Medical Officer1.4yrsno datano data

21.4yrs

Average Tenure

65yo

Average Age

Experienced Management: CANF's management team is seasoned and experienced (21.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Pnina Fishman
Founder19.3yrsUS$703.00k0.013%
₪ 5.3k
Ilan Cohn
Co-Founder & Director31yrsno data0.0065%
₪ 2.7k
Stephen A. Harrison
Member of Clinical Advisory Board & Consulting Chief Medical Officerno datano datano data
Nabil Hanna
Member of Scientific Advisory Boardno datano datano data
Yaacov Goldman
External Independent Director7.4yrsUS$60.00kno data
Abraham Sartani
Independent Director24yrsno datano data
Guy Regev
Independent External Director13.5yrsUS$60.00k0.0012%
₪ 486.5
Scott L. Friedman
Member of Clinical Advisory Boardno datano datano data
Arun Sanyal
Member of Clinical Advisory Boardno datano datano data
Yoseph Bornstein
Independent External Director3.4yrsno datano data
Rifaat Safadi
Member of Clinical Advisory Boardno datano datano data
Kim Papp
Member of Clinical Advisory Boardno datano datano data

16.4yrs

Average Tenure

70yo

Average Age

Experienced Board: CANF's board of directors are seasoned and experienced ( 16.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 02:32
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Can-Fite BioPharma Ltd. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCG Capital
Jason KolbertD. Boral Capital LLC.
Deepak SonawaneHaitong International Research Limited